European markets are experiencing significant labour shortages, a trend sharpened by all-time-high employee sickness rates. Employers are now increasingly relying on Occupational Health providers that promise lower employee absence days, better talent recruitment and higher workforce productivity. The growth drivers in these businesses combined low-regulation, predominantly B2B and stable revenue models makes it an attractive space for investors. This session explores how such services are impacting employee health and what the best model to win in the space is. How does integration with primary care, PMI and tech-enablement transform delivery and scale access?

Moderator and investment overview: Reiner Hepberger, Managing Director, Houlihan Lokey

Speakers:
Petri Bono, Chief Medical Officer, Terveystalo
Jack Latus, CEO, Latus Group
Alex Goldsmith, CEO, Medigold Health

Design thinking is deployed to get to the heart of complex issues, a step-by-step approach involving a lot of listening to ensure that ideas aren’t just creative but are effective and practical – ultimately ensuring that they get adopted. For healthcare CxOs, now is the perfect time to deploy the process with the sector adopting technology at breakneck speed ensuring the voices of all stakeholders are heard as new products, services and care delivery models are developed.

Join Craig Wills, CEO of Hi Mum! Said Dad (an L.E.K. company) and L.E.K.’s Katya Zubareva, Klaus Boehncke and Jacqueline Thompson for this breakfast at HBI 2024, sharing case studies into successful projects that followed this approach and demonstrating the concept, based on working with a leading fertility clinic.

Attendees will leave with a better understanding of the process and when and how to deploy design thinking. If you are developing new products and services, looking to enhance patient and clinician experience, solving complex challenges, or looking to drive change this breakfast is a must-attend.

We hope that you can join us for what is sure to be a lively and informative discussion – with complimentary breakfast!

Dentistry is one of the most attractive outpatient investment opportunities with an explosion in self-pay and governmental willingness to see change. This session explores what is driving demand, how to boost organic growth and the potential for further digital disruption.

This exclusive invitation-only event will bring together a community of healthcare CEOs and investors for networking and dinner. It is for leaders who are committed to working together to deliver a positive social impact in healthcare through their business activities.

At 4.5% of total emissions, healthcare emits twice as much greenhouse gas as aviation. The huge energy bills of recent months has thrust this issue further up the priority list, whilst patients, employees and investors place huge importance on environmental sustainability. This session features three healthcare value chain members discussing how they are reducing their environmental impact, including analysing supply chains, waste management and smart buildings.

Speakers include:

Tyson Welzel, Chief Innovation Officer, Mediclinic Group
Shikha Pillai, Global Head of Sustainability, Siemens Healthineers

Moderated by Ambika Jindal, Group Head Sustainability Integration & Implementation, ING Group

Healthcare’s stable and steady demand is attracting longer-term capital investors in infrastructure funds and family offices. So what does this new investor mean for the sector and for the businesses it is buying? What does value creation look like? How will this lead to the development of new delivery models and utilisation of community and urban space? This session featuring an Infrastructure investor and CEOs of infrastructure-owned providers includes a keynote from Italy’s Hippocrates Holdings. It will dive into the between this and other types of investors and discuss the opportunities in the market this new era heralds.

Keynote:
Davide Tavaniello, Co-CEO, Hippocrates

Panellists:
Rodolfo Guarino, Co-CEO, Hippocrates
Dr Angelika Schöchlin, Managing Partner, Antin Infastructure Partners

Despite optimism in the market and positive macro-economic winds forming, getting deals across the line continues to be a challenge, especially where bid-ask spreads remain wide. This keynote directly follows the Investment banking perspective on the M&A market to give the lawyer’s view, delving into recent deals and analysing the strategies deployed to avoid deals going missing or stalling.

Dr Stephan Rau, Partner, McDermott Will & Emery
Sharon Lamb, Partner, McDermott Will & Emery

Healthcare needs in emerging markets are considerable and are often not met by existing supply. Investors entering these markets have to be ready for risks, understanding how to spot them early and how to overcome them. This summit developed in partnership with the IFC includes leading investors and healthcare providers operating in emerging markets, sharing their insights, debating key topics and interactive roundtable discussions. 

14.00-14.30: Keynote: Lessons learned from investing in Emerging Markets
Farid Fezoua, Global Director, Health and Education, IFC

For the past 60 years, the IFC has been deploying private capital in emerging and developing markets, at present it has $3.5bn invested in healthcare businesses globally. Right now, emerging markets present an opportunity with huge potential but investors need to proceed with caution. In this opening keynote, Farid lays out the opportunities and gives advice on risks and how to overcome them, reflecting on the lessons the group has learned over the last half-century of investing. 

14.30-15.30: The investor’s viewpoint
Following the opening keynote, a panel of Investors from a broad range of geographies reflect on the topics raised and share their perspectives and lessons learned from their own experience whilst also taking questions from the audience. 
Speakers include: 
Afsane Jetha, Managing Partner and CEO, Alta Semper Capital
Matthew Strassberg, Partner, MidEuropa
Dr Abrar Mir, Managing Partner, Quadria Capital
Menka Shah, Partner, IFHA
Moderated by: Silven Chikengezha, Global Sector Lead, Health Services, IFC

15.30-16.15: Networking break

16.15-16.45: The audience’s viewpoint
Having heard the advice and opinions of investors, this interactive discussion is a chance for you, the audience, to share your reactions, debate ideas raised and to prompt further questions. 
Moderated by: Charles Dalton, Global Sector Specialist, Health, IFC.

16.45-17.45: The provider’s viewpoint
Having heard from investors about the opportunities emerging markets offer, here providers tell their stories and what it really takes to achieve growth. Do they agree with the advice investors offer or is their experience different? What is their advice and how can you use that in your own investment strategies?
Speakers include: 
Emmett Moriarty, Managing Director, Ennismore Advisory
Matt Williams, CEO, Africa Healthcare Network
Irfan Khan, Group Chief Commercial Officer & CEO, Evercare Group -Kenya, Nigeria, Pakistan
Dr Zoe Kyriakou, SVP Global Head of Healthcare Consulting, Siemens Healthineers
Moderated by: Raju Narayan, Global Sector Specialist, Health, IFC

17.45-18.00: Closing reflections
Farid Fezoua, Global Director, Health and Education, IFC
Having listened to the perspective of investors, the audience and providers, Farid summaries the key takeaway messages from the afternoon. 
 

How are providers assessing and extracting value from their data? How do you best analyse it to improve outcomes and patient experience? And how do you best analyse it to optimise workflow and patient throughput? Three case studies demonstrate what is possible and the pitfalls to avoid.

Speakers include:

Wolfgang Hofmann, Group Head Technology and Innovation, Fresenius Group
Wolfgang will share how Fresenius is approaching digitalisation, implementing generative AI and moving to the cloud in the complexity of a large organisational structure.
Prof Dr Jörg Debatin, Founder, Honic

Moderated by Alex Beauvais, Partner, McKinsey & Company

Nuclear medicine has long had its place in the diagnosis and treatment of disease, primarily in cardiology and oncology. Today, the nuclear medicine market is at an inflection point, as the rise of theragnostics and the advent of novel products is expected to nearly quadruple the size of the market in the next 10 years from ~$7bn to $25+bn by 2033. The enormous growth in the field is driven by continued radiopharmaceutical funding where 250+ trials are currently being conducted and by trial funding increasing ~45%+ p.a. between 2019 and 2022. This session features perspectives from a provider, radiopharmaceutical group and OEM on how this is accelerating growth, shaping the market and discussing the medium and long-term obstacles.

Moderation and market overview: Ian Poburenny, Director, Rothschild & Co

Speakers include:

Chait Tatineni, CEO International and Chief M&A Officer, Curium
Mark Chapman, CEO, Alliance Medical
Ben Newton, Global Head of Oncology, GE Healthcare